Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

133 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Hadziyannis SJ, et al. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. Ann Intern Med. 2004. PMID: 14996676 Clinical Trial.
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E. Wyles D, et al. Hepatology. 2015 Jun;61(6):1793-7. doi: 10.1002/hep.27814. Epub 2015 Apr 27. Hepatology. 2015. PMID: 25846014 Clinical Trial.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. Wedemeyer H, et al. Hepatology. 2013 Aug;58(2):524-37. doi: 10.1002/hep.26274. Epub 2013 Jun 26. Hepatology. 2013. PMID: 23348636 Clinical Trial.
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, Farci P, O'Brien CB, Lardelli P, Blotner S, Zeuzem S. Prati D, et al. J Hepatol. 2006 Apr;44(4):679-85. doi: 10.1016/j.jhep.2006.01.004. Epub 2006 Jan 25. J Hepatol. 2006. PMID: 16487620 Clinical Trial.
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group. Zeuzem S, et al. Gastroenterology. 2004 Dec;127(6):1724-32. doi: 10.1053/j.gastro.2004.09.050. Gastroenterology. 2004. PMID: 15578510 Clinical Trial.
Telaprevir for retreatment of HCV infection.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Zeuzem S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086. N Engl J Med. 2011. PMID: 21696308 Clinical Trial.
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Welzel TM, et al. Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13. Gut. 2017. PMID: 27418632 Free PMC article. Clinical Trial.
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.
Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Reddy KR, et al. Hepatology. 1999 Sep;30(3):787-93. doi: 10.1002/hep.510300319. Hepatology. 1999. PMID: 10462387 Clinical Trial.
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.
Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Shiffman ML, et al. Aliment Pharmacol Ther. 2010 May;31(9):969-78. doi: 10.1111/j.1365-2036.2010.04264.x. Epub 2010 Feb 16. Aliment Pharmacol Ther. 2010. PMID: 20163376 Clinical Trial.
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S. Zeuzem S, et al. J Viral Hepat. 2012 Nov;19(11):766-74. doi: 10.1111/j.1365-2893.2012.01624.x. Epub 2012 May 14. J Viral Hepat. 2012. PMID: 23043383
133 results
Jump to page
Feedback